Citius Pharmaceuticals (CTXR) Projected to Post Quarterly Earnings on Wednesday

Citius Pharmaceuticals (NASDAQ:CTXR) is projected to issue its quarterly earnings data on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.25) per share for the quarter.

Citius Pharmaceuticals Stock Performance

Shares of CTXR opened at $2.70 on Tuesday. The firm has a market cap of $23.19 million, a price-to-earnings ratio of -0.45 and a beta of 1.28. The firm has a 50 day moving average price of $3.24 and a 200-day moving average price of $9.24. Citius Pharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $26.75.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CTXR shares. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, January 7th.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.